Stock 6990 SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Stock

Equities

6990

CNE1000062J1

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 04:08:20 2024-04-26 am EDT 		5-day change 1st Jan Change
168 HKD +9.16% Intraday chart for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. +23.17% +63.27%
Apr. 15 Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan MT
Apr. 08 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024 CI

Financials

Sales 2024 * 1.16B 160M 1.25B Sales 2025 * 1.49B 205M 1.61B Capitalization 34.09B 4.7B 36.83B
Net income 2024 * -625M -86.26M -675M Net income 2025 * -684M -94.4M -739M EV / Sales 2024 * 29 x
Net cash position 2024 * 464M 64.07M 502M Net cash position 2025 * 639M 88.21M 690M EV / Sales 2025 * 22.5 x
P/E ratio 2024 *
-52.4 x
P/E ratio 2025 *
-48.3 x
Employees 1,446
Yield 2024 *
-
Yield 2025 *
-
Free-Float 55.25%
More Fundamentals * Assessed data

Chart Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Dynamic Chart

Latest news about Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Sichuan Kelun-Biotech Buys Structured Deposits Worth 680 Million Yuan MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Study Results for Core Product Scituzumab Turumotecan (SAC-TMT) at AACR Annual Meeting 2024 CI
Kelun-Biotech Shrinks Loss by 7% in 2023 MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
China Healthcare Stocks Rally on Hopes for Government Support DJ
China Grants Breakthrough Therapy Designation for Kelun-Biotech's Breast Cancer Treatment MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Its Core Product SKB264 (MK-2870) Granted Breakthrough Therapy Designation for First-Line Treatment of Unresectable Locally Advanced, Recurring or Metastatic Pd-L1 Negative Tnbc by the National Medical Products Administration CI
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Key Product A400 Granted Fast Track Designation by the US Food and Drug Administration CI
Kelun-Biotech Shares Start Trading in Shanghai's Southbound Stock Connect MT
Kelun-Biotech Licensee Starts Phase 3 Trials for Cancer Treatment; Shares Rise 5% MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Announces Collaboration with Merck Sharp & Dohme LLC CI
Kelun-Biotech Chosen as Constituent Stock of Hang Seng Indexes; Shares Fall 3% MT
Kelun-Biotech Controlling Shareholder Ups Stake; Shares Rise 4% MT
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.(SEHK:6990) added to S&P Global BMI Index CI
China Accepts Kelun-Biotech's Application for Triple-Negative Breast Cancer Treatment; Shares Fall 4% MT
More news

Quotes and Performance

1 day+9.16%
1 week+23.17%
Current month+8.39%
1 month+4.61%
3 months+98.82%
6 months+127.03%
Current year+63.27%
More quotes

Highs and lows

1 week
129.20
Extreme 129.2
169.80
1 month
129.20
Extreme 129.2
169.80
Current year
63.65
Extreme 63.65
177.90
1 year
60.60
Extreme 60.6
177.90
3 years
60.60
Extreme 60.6
177.90
5 years
60.60
Extreme 60.6
177.90
10 years
60.60
Extreme 60.6
177.90
More quotes

Managers and Directors - Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Managers TitleAgeSince
Jun You Ge CEO
 Chief Executive Officer 51 21-02-07
Ze Jian Zhou DFI
 Director of Finance/CFO 41 22-02-24
Xiang Yang Tan CTO
 Chief Tech/Sci/R&D Officer 61 21-07-04
Members of the board TitleAgeSince
Ge Xin Liu FOU
 Founder 73 16-11-21
Yue Dong Li BRD
 Director/Board Member 47 23-02-14
Si Chuan Liu BRD
 Director/Board Member 40 16-11-21
More insiders

Quotes

Date Price Change Volume
24-04-26 168 +9.16% 484,184
24-04-25 153.9 -0.06% 318,406
24-04-24 154 +4.19% 441,724
24-04-23 147.8 +5.95% 350,500
24-04-22 139.5 +2.27% 291,700

Delayed Quote Hong Kong S.E., April 26, 2024 at 04:08 am EDT

More quotes

Company Profile

Sichuan Kelun-Biotech Biopharmaceutical Co Ltd, formerly Sichuan Kelun Biotech Biopharmaceutical Co Ltd, is a China-based company mainly engaged in the research and development, production, and sales of drugs. The Company is mainly engaged in the research and development, production, and sales of biopharmaceuticals, chemical raw materials, and chemical drug formulations. The Company's products are mainly used for the treatment of breast cancer, non-small cell lung cancer, Gastrointestinal cancer and other non tumor diseases.
Sector
Biotechnology & Medical Research
Calendar
2024-08-27 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Ratings for Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
11
Last Close Price
168 HKD
Average target price
182.8 HKD
Spread / Average Target
+8.81%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
+63.27% 4.7B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 6990 Stock